Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course Dual HER2 Blockade in Early Breast Cancer
NCT05891561Phase 2Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab in breast cancer, sponsored by Shanghai Jiao Tong University School of Medicine. Started Nov 2023; status: recruiting.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05891561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05891561.